Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22840863 | 1.00 | KDM4E (0.55) | KDM4EALDH1A1POLBGAATSHR | |
| SCHEMBL503668 | 0.98 | KDM4E (0.57) | KDM4EALDH1A1POLBGAATSHR | |
| SCHEMBL18024033 | 0.90 | KDM4E (0.53) | KDM4EALDH1A1POLBGAATSHR | |
| SCHEMBL7106263 | 0.89 | TSHR (0.61) | KDM4EALDH1A1POLBTSHRL3MBTL1 | |
| SCHEMBL111438 | 0.87 | TSHR (0.58) | KDM4EALDH1A1TSHRSMN1; SMN2KEAP1 | |
| SCHEMBL4376068 | 0.86 | ALDH1A1 (0.53) | KDM4EALDH1A1POLBGAATSHR | |
| SCHEMBL31305372 | 0.85 | MEN1 (0.55) | KDM4EALDH1A1TSHRSMN1; SMN2MEN1 | |
| SCHEMBL31305373 | 0.85 | MEN1 (0.55) | KDM4EALDH1A1TSHRSMN1; SMN2MEN1 | |
| SCHEMBL20118622 | 0.83 | KDM4E (0.54) | KDM4EALDH1A1POLBGAATSHR | |
| SCHEMBL8966405 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117362332-A | Binary phthalocyanine with I-type photosensitive reaction and photo-thermal synergistic effect and preparation and application thereof | 福州大学 | 2024-01-09 | — | — | CN | claimed |
| CN-121577501-A | Polypeptide aggregation trend prediction method based on dynamic light scattering | 中肽生化有限公司 | 2026-02-27 | — | — | CN | disclosed |
| CN-117362332-A | Binary phthalocyanine with I-type photosensitive reaction and photo-thermal synergistic effect and preparation and application thereof | 福州大学 | 2024-01-09 | — | — | CN | disclosed |
| EP-2981535-B1 | UREA DERIVATIVES USEFUL AS KINASE INHIBITORS | TOPIVERT PHARMA LTD (GB) | 2020-12-16 | — | — | EP | disclosed |
| US-10435361-B2 | Kinase inhibitors | TOPIVERT PHARMA LIMITED (GB) | 2019-10-08 | — | — | US | disclosed |
| EP-3111940-B1 | SILICON PHTHALOCYANINE COMPLEX, PREPARATION METHOD AND MEDICINAL APPLICATION THEREOF | SHENZHEN CHINA RESOURCES GOSUN PHARMACEUTICAL CO LTD (CN) | 2018-03-21 | — | — | EP | disclosed |
| US-20180044288-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2018-02-15 | — | — | US | disclosed |
| US-9890181-B2 | Silicon phthalocyanine complex, preparation method and medicinal application thereof | SHENZHEN CHINA RESOURCES GOSUN PHARMACEUTICAL CO., LTD. (CN) | 2018-02-13 | — | — | US | disclosed |
| US-9790174-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-10-17 | — | — | US | disclosed |
| US-9732063-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-08-15 | — | — | US | disclosed |
| US-9056914-B2 | Anticancer derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2015-06-16 | — | — | US | disclosed |
| WO-2014162126-A1 | UREA DERIVATIVES USEFUL AS KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2014-10-09 | — | — | WO | disclosed |
| US-20140296208-A1 | KINASE INHIBITORS | TOPIVERT PHARMA LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| WO-2014076484-A1 | KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2014-05-22 | — | — | WO | disclosed |
| EP-2598507-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-06-05 | — | — | EP | disclosed |
| US-20130137659-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-30 | — | — | US | disclosed |
| US-20130137659-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-30 | — | — | US | disclosed |
| US-20130137659-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-30 | — | — | US | disclosed |
| WO-2012014147-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012014147-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044288-A1 | KINASE INHIBITORS | SYK, LYN, BTK | KDM4E 1018/4885ALDH1A1 4408/4885POLB 3321/4885 |
| US-20130137659-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | MCL1, TP53, MYC | KDM4E 2894/4885ALDH1A1 339/4885POLB 1182/4885 |
| US-10435361-B2 | Kinase inhibitors | SYK, LYN, BTK | KDM4E 1018/4885ALDH1A1 4408/4885POLB 3321/4885 |
| US-20140296208-A1 | KINASE INHIBITORS | SYK, LYN, BTK | KDM4E 1018/4885ALDH1A1 4408/4885POLB 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.